Fig. 2 | npj Vaccines

Fig. 2

From: Overcoming immunogenicity issues of HIV p24 antigen by the use of innovative nanostructured lipid carriers as delivery systems: evidences in mice and non-human primates

Fig. 2

Immunogenic properties of NLC formulations. a Antigen presentation by primary DC to anti-OVA T lymphocytes. Secretion of IL-13 and IFN-γ by T lymphocytes after 4 days of co-culture with DC previously stimulated with formulations combining OVA and CpG. Bars indicate the standard error of the mean calculated on three measurements. b Humoral response in mice as measured based on serum anti-p24 and anti-OVA antibody levels and c cell-mediated response as determined based on the secretion of IFN-γ by T lymphocytes from the spleen of immunized mice after in vitro antigen stimulation. Mice were immunized with both p24 and OVA formulations (5 µg p24 and 10 µg OVA) co-administered with 10 µg CpG. Each point represents an individual mouse, horizontal bars represent the mean for the group and vertical bars indicate the standard error of the mean. Data were compared between groups using a 1-way ANOVA test followed by Fisher’s protected least significant difference test. ***p < 0.001

Back to article page